Cargando…
Economic Value of Dengue Vaccine in Thailand
With several candidate dengue vaccines under development, this is an important time to help stakeholders (e.g., policy makers, scientists, clinicians, and manufacturers) better understand the potential economic value (cost-effectiveness) of a dengue vaccine, especially while vaccine characteristics...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
The American Society of Tropical Medicine and Hygiene
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083745/ https://www.ncbi.nlm.nih.gov/pubmed/21540387 http://dx.doi.org/10.4269/ajtmh.2011.10-0624 |
_version_ | 1782202447542878208 |
---|---|
author | Lee, Bruce Y. Connor, Diana L. Kitchen, Sarah B. Bacon, Kristina M. Shah, Mirat Brown, Shawn T. Bailey, Rachel R. Laosiritaworn, Yongjua Burke, Donald S. Cummings, Derek A. T. |
author_facet | Lee, Bruce Y. Connor, Diana L. Kitchen, Sarah B. Bacon, Kristina M. Shah, Mirat Brown, Shawn T. Bailey, Rachel R. Laosiritaworn, Yongjua Burke, Donald S. Cummings, Derek A. T. |
author_sort | Lee, Bruce Y. |
collection | PubMed |
description | With several candidate dengue vaccines under development, this is an important time to help stakeholders (e.g., policy makers, scientists, clinicians, and manufacturers) better understand the potential economic value (cost-effectiveness) of a dengue vaccine, especially while vaccine characteristics and strategies might be readily altered. We developed a decision analytic Markov simulation model to evaluate the potential health and economic value of administering a dengue vaccine to an individual (≤ 1 year of age) in Thailand from the societal perspective. Sensitivity analyses evaluated the effects of ranging various vaccine (e.g., cost, efficacy, side effect), epidemiological (dengue risk), and disease (treatment-seeking behavior) characteristics. A ≥ 50% efficacious vaccine was highly cost-effective [< 1× per capita gross domestic product (GDP) ($4,289)] up to a total vaccination cost of $60 and cost-effective [< 3× per capita GDP ($12,868)] up to a total vaccination cost of $200. When the total vaccine series was $1.50, many scenarios were cost saving. |
format | Text |
id | pubmed-3083745 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | The American Society of Tropical Medicine and Hygiene |
record_format | MEDLINE/PubMed |
spelling | pubmed-30837452011-05-17 Economic Value of Dengue Vaccine in Thailand Lee, Bruce Y. Connor, Diana L. Kitchen, Sarah B. Bacon, Kristina M. Shah, Mirat Brown, Shawn T. Bailey, Rachel R. Laosiritaworn, Yongjua Burke, Donald S. Cummings, Derek A. T. Am J Trop Med Hyg Articles With several candidate dengue vaccines under development, this is an important time to help stakeholders (e.g., policy makers, scientists, clinicians, and manufacturers) better understand the potential economic value (cost-effectiveness) of a dengue vaccine, especially while vaccine characteristics and strategies might be readily altered. We developed a decision analytic Markov simulation model to evaluate the potential health and economic value of administering a dengue vaccine to an individual (≤ 1 year of age) in Thailand from the societal perspective. Sensitivity analyses evaluated the effects of ranging various vaccine (e.g., cost, efficacy, side effect), epidemiological (dengue risk), and disease (treatment-seeking behavior) characteristics. A ≥ 50% efficacious vaccine was highly cost-effective [< 1× per capita gross domestic product (GDP) ($4,289)] up to a total vaccination cost of $60 and cost-effective [< 3× per capita GDP ($12,868)] up to a total vaccination cost of $200. When the total vaccine series was $1.50, many scenarios were cost saving. The American Society of Tropical Medicine and Hygiene 2011-05-05 /pmc/articles/PMC3083745/ /pubmed/21540387 http://dx.doi.org/10.4269/ajtmh.2011.10-0624 Text en ©The American Society of Tropical Medicine and Hygiene http://creativecommons.org/licenses/by/2.5/ This is an Open Access article distributed under the terms of the American Society of Tropical Medicine and Hygiene's Re-use License which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Articles Lee, Bruce Y. Connor, Diana L. Kitchen, Sarah B. Bacon, Kristina M. Shah, Mirat Brown, Shawn T. Bailey, Rachel R. Laosiritaworn, Yongjua Burke, Donald S. Cummings, Derek A. T. Economic Value of Dengue Vaccine in Thailand |
title | Economic Value of Dengue Vaccine in Thailand |
title_full | Economic Value of Dengue Vaccine in Thailand |
title_fullStr | Economic Value of Dengue Vaccine in Thailand |
title_full_unstemmed | Economic Value of Dengue Vaccine in Thailand |
title_short | Economic Value of Dengue Vaccine in Thailand |
title_sort | economic value of dengue vaccine in thailand |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083745/ https://www.ncbi.nlm.nih.gov/pubmed/21540387 http://dx.doi.org/10.4269/ajtmh.2011.10-0624 |
work_keys_str_mv | AT leebrucey economicvalueofdenguevaccineinthailand AT connordianal economicvalueofdenguevaccineinthailand AT kitchensarahb economicvalueofdenguevaccineinthailand AT baconkristinam economicvalueofdenguevaccineinthailand AT shahmirat economicvalueofdenguevaccineinthailand AT brownshawnt economicvalueofdenguevaccineinthailand AT baileyrachelr economicvalueofdenguevaccineinthailand AT laosiritawornyongjua economicvalueofdenguevaccineinthailand AT burkedonalds economicvalueofdenguevaccineinthailand AT cummingsderekat economicvalueofdenguevaccineinthailand |